Altimmune (NASDAQ:ALT) First Half 2024 Results

Key financial results

All figures shown in the graph above refer to the last 12 months (TTM)

Altimmune sales exceed expectations, EPS falls short of expectations

Sales exceeded analysts’ estimates. Earnings per share (EPS) missed analysts’ estimates by 1.4%.

An average sales growth of 72% per year is expected for the next three years. In the US biotech industry, however, growth of 23% is forecast.

Performance of American biotechnology industry.

The company’s shares rose 2.8% compared to the previous week.

Risk analysis

And what about the risks? Every company has them, and we have 4 Warning Signs for Altimmune (1 of them a bit unpleasant!) that you should know.

Do you have feedback on this article? Are you concerned about the content? Contact us directly from us. Alternatively, send an email to editorial-team (at) simplywallst.com.

This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.